MedTrace Logo

Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents

NCT01245374 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2017-02-27

Study results available
· View outcomes & findings →

Summary

This study is conducted in Europe. The aim of this study is to compare the easiness of use of Norditropin NordiFlex® device to the device previously used by patients or parents.

Conditions

  • Growth Hormone Disorder
  • Growth Hormone Deficiency in Children
  • Foetal Growth Problem
  • Small for Gestational Age
  • Genetic Disorder
  • Turner Syndrome
  • Chronic Kidney Disease
  • Chronic Renal Insufficiency
  • Delivery Systems

Interventions

DEVICE

Norditropin NordiFlex®

Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • France

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245374 on ClinicalTrials.gov